BioCentury
ARTICLE | Clinical News

DI-B4: Phase I started

February 10, 2014 8:00 AM UTC

Cancer Research U.K. (London, U.K.) said its Drug Development Office ( DDO) began an open-label, dose-escalation, U.K. Phase I trial to evaluate IV DI-B4 weekly for 4 weeks in about 40 patients with r...